RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 16 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 16

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteCancer Hospital, Shandong First Medical University山东省肿瘤医院JinanHospital page
  2. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  3. Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
  4. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  5. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  6. Study siteFirst People's Hospital of Foshan佛山市第一人民医院FoshanHospital page
  7. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  8. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  9. Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page
  10. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  11. Study siteShandong Provincial Hospital山东省立医院JinanHospital page
  12. Study siteShenzhen People's Hospital深圳市人民医院ShenzhenHospital page
  13. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  14. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
  15. Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
  16. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07541170, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histological or cytological diagnosis of clinical Stage II-IIIB NSCLC of either non-squamous or squamous histology

    Inclusion criterion 2

    Prior treatment with neoadjuvant immune checkpoint inhibitor (pembrolizumab or nivolumab) in combination with histology-based platinum-based doublet chemotherapy

    Inclusion criterion 4

  3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

    Inclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07541170, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Histological or cytological diagnosis of clinical Stage II-IIIB NSCLC of either non-squamous or squamous histology
  • Participants must have had complete resection of NSCLC
  • Prior treatment with neoadjuvant immune checkpoint inhibitor (pembrolizumab or nivolumab) in combination with histology-based platinum-based doublet chemotherapy
  • Participants must be randomized within 12 weeks of their surgery date
  • No evidence of disease recurrence or metastatic disease
  • Documentation of the presence of a KRAS G12C mutation

Exclusion Criteria:

  • Participants who achieve pCR following neoadjuvant treatment
  • Prior treatment with a KRAS inhibitor or any other anti-cancer therapy not otherwise specified in the protocol
  • Prior treatment with radiation therapy for NSCLC, with the exception of localized symptom-directed radiation prior to surgical resection
  • Resolved Grade 3 or greater immune-related AE or unresolved Grade 2 or greater immune-related AE from neoadjuvant immunotherapy
  • Active or history of autoimmune disease or immune deficiency
  • Significant cardiovascular disease

Quoted from ClinicalTrials.gov, NCT07541170, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07541170, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07541170